Wed, Apr 16, 2014, 7:50 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • insm_truth_teller insm_truth_teller Aug 21, 2013 8:58 PM Flag

    Unable to estimate at this time tom.berry169 •

    That question is way above my pay grade. There are far too many variables for me or any rational human being to come up with an estimate. FDA approval is never a slam dunk (see DVAX in November 2012 and Feb 2013 for a superior drug that was involved in a 4,500-patient Phase III trial).
    In a perfect analytical world, a stock's value is based on a stream of future cash flow. Approval, potential future competitors, actual performance of the drug after it's been approved, price level for treatment, acceptance by the medical community and by patients - there are a lot of moving parts.
    My previous post wasn't so much about valuation as it was about the incestuous way Wall Street works. Company shows an interest in raising $ through a stock offering, investment banks bid for the business, analysts at said investment banks put out research to justify the offering, stock gets peddled

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • That question is way above my pay grade. There are far too many variables for me or any rational human being to come up with an estimate. FDA approval is never a slam dunk (see DVAX in November 2012 and Feb 2013 for a superior drug that was involved in a 4,500-patient Phase III trial).
      In a perfect analytical world, a stock's value is based on a stream of future cash flow. Approval, potential future competitors, actual performance of the drug after it's been approved, price level for treatment, acceptance by the medical community and by patients - there are a lot of moving parts.
      My previous post wasn't so much about valuation as it was about the incestuous way Wall Street works. Company shows an interest in raising $ through a stock offering, investment banks bid for the business, analysts at said investment banks put out research to justify the offering, stock gets peddled

      • 1 Reply to insm_truth_teller
      • Reply to Unable to estimate at this time tom.berry169 • by insm_truth_teller •Aug 21, 2013 8:58 PM
        insm_truth_teller • Aug 22, 2013 4:10 AM 3users liked this postsusers disliked this posts5Reply
        That question is way above my pay grade. There are far too many variables for me or any rational human being to come up with an estimate. FDA approval is never a slam dunk (see DVAX in November 2012 and Feb 2013 for a superior drug that was involved in a 4,500-patient Phase III trial).
        In a perfect analytical world, a stock's value is based on a stream of future cash flow. Approval, potential future competitors, actual performance of the drug after it's been approved, price level for treatment, acceptance by the medical community and by patients - there are a lot of moving parts.
        My previous post wasn't so much about valuation as it was about the incestuous way Wall Street works. Company shows an interest in raising $ through a stock offering, investment banks bid for the business, analysts at said investment banks put out research to justify the offering, stock gets peddled

    • That question is way above my pay grade. There are far too many variables for me or any rational human being to come up with an estimate. FDA approval is never a slam dunk (see DVAX in November 2012 and Feb 2013 for a superior drug that was involved in a 4,500-patient Phase III trial).
      In a perfect analytical world, a stock's value is based on a stream of future cash flow. Approval, potential future competitors, actual performance of the drug after it's been approved, price level for treatment, acceptance by the medical community and by patients - there are a lot of moving parts.
      My previous post wasn't so much about valuation as it was about the incestuous way Wall Street works. Company shows an interest in raising $ through a stock offering, investment banks bid for the business, analysts at said investment banks put out research to justify the offering, stock gets peddled
      .
      ..

      .
      ..
      .
      .
      ..

      • 1 Reply to insm_truth_teller
      • That question is way above my pay grade. There are far too many variables for me or any rational human being to come up with an estimate. FDA approval is never a slam dunk (see DVAX in November 2012 and Feb 2013 for a superior drug that was involved in a 4,500-patient Phase III trial).
        In a perfect analytical world, a stock's value is based on a stream of future cash flow. Approval, potential future competitors, actual performance of the drug after it's been approved, price level for treatment, acceptance by the medical community and by patients - there are a lot of moving parts.
        My previous post wasn't so much about valuation as it was about the incestuous way Wall Street works. Company shows an interest in raising $ through a stock offering, investment banks bid for the business, analysts at said investment banks put out research to justify the offering, stock gets peddled

 
INSM
12.53-0.04(-0.32%)Apr 16 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.